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EDITORIAL COMMENT
To C or Not to C,
That Is the Question!*
Balz Frei, PHD
Corvallis, Oregon
In this issue of the Journal, Osganian et al. (1) in Dr. Walter
Willett’s group at Harvard University report that women in
the Nurses’ Health Study who took vitamin C supplements
had a significantly lower risk of incident coronary heart
disease (CHD) than women who did not take vitamin C
supplements. The risk reduction with vitamin C supple-
ment use was 28% after adjusting for age, smoking, and
several other coronary risk factors, vitamins, and dietary
antioxidants such as vitamin E and carotenes. In contrast,
vitamin C from dietary intake alone was not significantly
associated with a reduced CHD risk. After all the contro-
versy and overall disappointing results with beta-carotene
and vitamin E supplementation for secondary prevention of
CHD, could vitamin C be the saving grace for a cardiopro-
tective role of antioxidant vitamins?
See page 246
The totality of evidence from past population-based
studies suggests that low or deficient intakes of vitamin C
are associated with an increased CHD risk and that a
modest intake of about 100 mg/day is sufficient for maxi-
mum reduction of CHD risk by vitamin C among non-
smoking men and women (2). This conclusion is buttressed
by several studies showing no benefit of higher vitamin C
intakes in well-nourished populations consuming close to
100 mg/day in the lowest quantile and no CHD risk
reduction among vitamin C supplement users (2). The
100-mg threshold for maximum CHD benefits also seems
reasonable in light of pharmacokinetic data showing that
this dose of vitamin C is associated with near-saturation of
circulating cells and, thus, presumably tissues and the
vitamin C body pool in both men (3) and women (4).
One notable exception for a lack of effect of vitamin C
supplementation on CHD risk is the First National Health
and Nutrition Examination Study (NHANES I) Epidemi-
ologic Follow-up Study (5). This study found a 45% and
25% reduced CHD risk in men and women, respectively,
consuming 50 mg/day of vitamin C from the diet and
taking regular supplements, corresponding to a total vitamin
C intake of about 300 mg/day (6). The study of Osganian et
al. (1) appears to confirm the conclusion of the NHANES
I study (5) that vitamin C supplementation lowers CHD
risk in women by about 25%. However, an important
difference is that the NHANES I study, unlike the present
study, did not adjust for vitamin E intake or supplementa-
tion, which may contribute to the primary prevention of
CHD (7).
The finding that vitamin C intake from diet alone, in
contrast to vitamin C supplements, was not associated with
a reduced CHD risk (1) raises at least two intriguing issues.
First, it implies that the amounts of vitamin C derived from
the diet, even in this well-nourished cohort of female nurses
with a median dietary vitamin C intake of 209 mg/day in
the highest quintile, is not sufficient to provide protection
against CHD. In contrast, a vitamin C intake of 359
mg/day from diet plus supplements or supplement use itself
was associated with a significant 27% to 28% reduction in
risk (1). The recently revised recommended dietary allow-
ance for vitamin C in women is 75 mg/day (8), far from
providing cardioprotective benefits if the current data are
confirmed.
Based on detailed pharmacokinetic data of vitamin C in
healthy young women (4), the dietary intake range in
Osganian’s study (61 to 209 mg/day of vitamin C, median
intake in lowest vs. highest quintile) encompasses the steep
portion of the dose-response curve for plasma vitamin C
levels, in contrast to the median vitamin C intake in
non-supplement users (132 mg/day) and supplement users
(672 mg/day) (Fig. 1). Thus, on the basis of these pharma-
cokinetic data (4) and the above-mentioned threshold of
about 100 mg/day for near-saturation of cells, one might
expect to find a stronger association of CHD risk with
dietary intake of vitamin C than with vitamin C supple-
mentation. This apparent incompatibility of the pharmaco-
kinetic (4) with the observational data (1) could be ex-
plained by differences in the subjects studied, such as age,
menopausal status, or lifestyle, and by the inherent difficul-
ties of accurately assessing vitamin C intake in epidemio-
logic studies (as described later). On the other hand, the
vitamin C pharmacokinetic study (4) also showed that
plasma (Fig. 1) and circulating cells only fully saturate at a
daily dose of 400 mg of vitamin C. Consequently, the
cardioprotective effect of vitamin C may become manifest
only when plasma and cells, and presumably tissues, are
completely saturated with the vitamin, thus making the two
studies potentially compatible (1,4).
Second, the fact that vitamin C intake from diet alone, in
contrast to vitamin C supplements, was not associated with
a reduced CHD risk (1) implies that vitamin C itself is
beneficial. Most previous studies that found an inverse
association between dietary intake or plasma levels of
vitamin C and CHD risk interpreted these results as an
indication of a protective role of fruit and vegetable con-
sumption (2,9). Similar to beta-carotene, vitamin C was
presumed to be a marker of fruit and vegetable intake, rather
than the cardioprotective component itself. This notion
turned out to be largely correct with respect to beta-
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carotene, as beta-carotene supplementation in randomized,
placebo-controlled clinical trials, both for primary (10) and
secondary prevention (11), exerted no CHD benefits. How-
ever, corresponding data from clinical trials of vitamin C
supplementation are currently unavailable.
An alternative interpretation of the lower CHD inci-
dence rates in vitamin C supplement users versus nonusers
is that supplement use may reflect other healthy behaviors.
Indeed, the vitamin C supplement users compared with
non-users had higher intakes of numerous other vitamins
derived from both diet and supplements, were more phys-
ically active and less likely to smoke, and took more aspirin
(1). Despite adjustment for these and other known coronary
risk factors, residual confounding can never be excluded in
any observational study.
We are still left with a conundrum: why did most
previous studies observe a reduced CHD risk within the
dietary vitamin C intake range and maximal beneficial
effects at an intake of about 100 mg/day, but not with
vitamin C supplementation (2,9)? One possible explanation
is that the semiquantitative food frequency questionnaire
used by Osganian et al. (1) is not sensitive enough to detect
small differences in CHD risk. Indeed, investigators of the
EPIC-Norfolk Prospective Study (9) found a strong inverse
association between CHD mortality and plasma vitamin C
levels or vitamin C intake assessed by a seven-day diet diary,
but not with a semiquantitative food frequency question-
naire. Thus, a significant association in the present study (1)
may have been observed for supplemental vitamin C only
because supplemental intake is relatively easy to assess (i.e.,
it is possible for subjects to remember the dose of supple-
ments and the frequency of their use). In contrast, assess-
ment of dietary intake by food frequency questionnaire is
less precise and does not take into account loss of vitamin C
during food storage or preparation. Nevertheless, the cur-
rent data (1) suggest that vitamin C itself has a beneficial
effect on CHD risk and is not just a marker of fruit and
vegetable intake (9).
Although the degree of protection and the required dose
of vitamin C are debatable, one clear finding of Osganian’s
study is that vitamin C supplementation does not increase
CHD risk. One recent study has suggested that combined
treatment with vitamin C (1,000 mg/day) and vitamin E
(800 IU/day) increases the risk of death and nonfatal
myocardial infarction in postmenopausal women, although
the only significant effect of supplementation was on deaths
from all causes combined (12). This is most likely a chance
finding, given the small number of subjects (n  423) and
the much smaller number of deaths during the 4.5 years of
the study (16 in the active group vs. 6 in the placebo group).
In contrast, the current study prospectively followed 85,118
Figure 1. Steady-state vitamin C plasma concentrations as a function of dose in women. Fifteen healthy nonsmoking women (ages 19 to 27 years, body
mass index 22.3  2.7 kg/m2) living in a hospital ward were depleted of vitamin C, and then repleted in succession with daily vitamin C doses of 30, 60,
100, 200, 400, 1,000, and 2,500 mg. Doses through 200 mg daily were received by 15 subjects, through 1,000 mg by 13 subjects, and through 2,500 mg
by 10 subjects. Median vitamin C intakes from the diet in the lowest and highest quintile, as well as median vitamin C intakes in users and non-users of
vitamin C supplements in the study by Osganian et al. (1) are also shown, with multivariate-adjusted relative risk (RR) for coronary heart disease. *Statistical
significance (confidence interval 0.61 to 0.86). Adapted from ref. 4.
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female nurses for 16 years with 1,356 incident cases of
CHD (1).
What might be the mechanism by which vitamin C
lowers CHD risk? In addition to acting as the first line of
antioxidant defense in plasma (13) and effectively inhibiting
low-density lipoprotein oxidation (14), and thus potentially
atherosclerotic lesion formation (2), vitamin C has been
shown to play a pivotal role in maintaining normal endo-
thelial function. In particular, endothelial synthesis of nitric
oxide (NO) is impaired in patients with CHD or coronary
risk factors, and NO is known to cause vasodilation and
inhibit platelet aggregation and thrombus formation, thus
inhibiting clinical expression of CHD (15). A large number
of clinical trials has demonstrated that vitamin C treatment,
either orally or by intravenous infusion, increases NO
bioactivity in patients with CHD or coronary risk factors, as
measured by brachial or coronary artery vasodilation (2).
The underlying mechanism by which vitamin C enhances
endothelial NO synthase activity is by maintaining its
essential cofactor, tetrahydrobiopterin, in the reduced, and
thus active, form (16).
Is vitamin C ready for prime time in randomized,
placebo-controlled clinical trials? Even though this latest
study is encouraging, a number of questions remain unan-
swered. What is the effective dose? Does vitamin C itself
protect? Which populations will benefit the most from
vitamin C supplements? Is vitamin C effective in primary
prevention only, as suggested by the current study, or will
the data hold up in secondary prevention, especially if
combined with standard drug therapy for CHD? The effects
of vitamin C supplementation should be tested in popula-
tions that have low or deficient dietary vitamin C intakes in
the lowest quantile, to make sure the subjects are not already
saturated with vitamin C and to provide adequate statistical
power for the study. A supplement of 500 mg/day seems
reasonable to ensure that plasma and tissues in all subjects
will become fully saturated. Plasma vitamin C levels, in vivo
markers of oxidative stress, and possibly NO bioactivity
need to be monitored before, during, and at the conclusion
of the study, to identify those subjects that may benefit the
most from antioxidant supplementation and to confirm that
the treatment had the intended effects. Although results
from such well-designed secondary prevention trials may be
forthcoming, we may never know with certainty whether
vitamin C supplementation is of benefit in the primary
prevention of CHD, as such long-term trials may be
prohibitively expensive and impractical. What we know
with certainty, however, is that a healthy diet and lifestyle
lowers the risk of CHD (17), and this is what we should
advocate to CHD patients and healthy people alike. An
additional multivitamin/multimineral supplement as a
“health insurance” also is sensible advice (18), as may be a
vitamin C supplement to help lower CHD risk.
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